SCHEMBL17028616

SCHEMBL17028616

O=Cc1ccc(OCc2cc(F)ccc2Br)cn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.39
KMT2A Q03164 2/20 0.39
NPC1 O15118 1/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.39
HPGD P15428 1/20 0.39
MAOB P27338 3/20 0.37
MAOA P21397 2/20 0.37
FFAR4 Q5NUL3 4/20 0.36
ALKBH1 Q13686 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
GSK3B P49841 2/20 0.36
BACE1 P56817 2/20 0.36
GAA P10253 1/20 0.34
FFAR1 O14842 1/20 0.33
MMP1 P03956 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17028729 0.84 GSK3B (0.42) ALDH1A1KMT2AMEN1MAOBFFAR4
SCHEMBL17028728 0.84 GSK3B (0.42) ALDH1A1KMT2AMEN1MAOBFFAR4
SCHEMBL755968 0.77 MAOB (0.56) ALDH1A1MAOBMAOAALKBH1L3MBTL1
SCHEMBL6873030 0.76 MAOB (0.64) MAOBMAOAALKBH1
SCHEMBL21580156 0.75 MAOB (0.50) NPC1RAB9ASMN1; SMN2MAOBALKBH1
SCHEMBL17028609 0.72 FFAR4 (0.56) FFAR4FFAR1
SCHEMBL6873145 0.71 MAOB (0.51) NPC1RAB9AMAOBMAOA
SCHEMBL16838775 0.70 L3MBTL1 (0.53) ALDH1A1KMT2AHTTSMN1; SMN2MEN1
SCHEMBL13754894 0.70 MAOB (0.52) ALDH1A1MAPTHPGDMAOBFFAR4
SCHEMBL1562628 0.70 MAOB (0.52) ALDH1A1MAPTHPGDMAOBFFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3107901-B1 COMPOUNDS FOR USE AS GPR120 AGONISTS PIRAMAL ENTPR LTD (IN) 2020-04-01 EP disclosed
US-10227360-B2 Compounds for use as GPR120 agonists Piramal Enterprises Limited (IN) 2019-03-12 US disclosed
EP-3107901-A1 COMPOUNDS FOR USE AS GPR120 AGONISTS Piramal Enterprises Limited (IN) 2016-12-28 EP disclosed
US-20160347768-A1 COMPOUNDS FOR USE AS GPR120 AGONISTS Piramal Enterprises Limited (IN) 2016-12-01 US disclosed
WO-2015125085-A1 COMPOUNDS FOR USE AS GPR120 AGONISTS Piramal Enterprises Limited (IN) 2015-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10227360-B2 Compounds for use as GPR120 agonists GPR119, GPR55, GPR180 ALDH1A1 2823/4885KMT2A 4028/4885NPC1 785/4885
US-20160347768-A1 COMPOUNDS FOR USE AS GPR120 AGONISTS GPR119, GPR55, GPR180 ALDH1A1 2823/4885KMT2A 4028/4885NPC1 785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.